arrow
N

Nicole Korman

Queensland Centre for Mental Health Research
H指数:15
被引数:648

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SMART: preliminary efficacy; feasibility and acceptability of a theory-informed digital intervention for metabolic health in people with schizophrenia and related disorders

SMART研究:基于理论指导的数字干预措施对精神分裂症及相关障碍患者代谢健康的初步疗效、可行性与可接受性

2026-04-270
OA
Supporting Staff To Address the Physical Health of Consumers in Mental Healthcare Settings: A Modified Nominal Group Technique

支持精神医疗环境中工作人员应对消费者的身体健康:一种改良的命名小组技术

2026-01-010
OA
The feasibility of resistance training versus aerobic exercise in a rehabilitation setting for people living with psychotic disorders: A randomised controlled trial

对于患有精神病障碍人群在康复环境中进行抗阻训练与有氧运动的可行性比较:一项随机对照试验

2025-11-110
PRE
An Effectiveness Trial of an Exercise Physiologist Service to Improve Quality of Life in Adults with Severe Mental Illness: Protocol for the MOVEMENT Study

一项运动生理学家服务以提高严重精神疾病成人生活质量的有效性试验:MOVEMENT研究的方案

2025-07-110
OA
Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panel

中性粒细胞绝对计数及氯氮平治疗期间的不良药物反应监测:全球德尔菲专家组共识指南

2025-07-020
PRE
A Novel Digital Intervention to Facilitate Diabetes Self-Management Among People with Schizophrenia and Related Disorders: Development and Acceptability Testing of SMART

一种新型数字干预措施,用于促进精神分裂症及相关障碍患者中的糖尿病自我管理:SMART的开发与可接受性测试

2025-06-260
OA
Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia

司美格鲁肽相对于安慰剂在服用氯氮平并伴有肥胖的精神分裂症患者中的疗效与安全性(COaST):一项在澳大利亚进行的第2阶段、多中心、参与者与研究者双盲、随机对照试验

2025-06-100
PRE